Study
GlyNAC Reversed 9 Hallmarks of Aging in Humans
GlyNAC (glycine + N-acetylcysteine) supplementation reversed 9 of 12 hallmarks of aging in older adults.
Summary Can GlyNAC make older people biologically healthier? Show / hide ↓
Researchers ran a controlled trial in older adults who took GlyNAC, a combination of glycine and N-acetylcysteine. They assessed 12 “hallmarks of aging,” meaning biological changes linked with getting older, such as oxidative stress, cell damage caused by unstable molecules, and mitochondrial dysfunction, problems with the cell parts that make energy. The researchers reported improvement in 9 of the 12 measures. The available information does not state how many people took part, how long the trial lasted, or whether the changes improved health or lengthened life.
What this means for you: This report is not enough to justify buying GlyNAC for slowing aging. The missing details and focus on biological measures, rather than meaningful health outcomes, make the result uncertain.
weak evidenceA Baylor University trial found that GlyNAC supplementation (glycine + N-acetylcysteine) reversed multiple aging hallmarks in humans. The trial reported reversal of 9 of the 12 classical hallmarks of aging, including oxidative stress, mitochondrial dysfunction, and inflammation. This is notable because GlyNAC is a simple, inexpensive combination of two amino acids, not a proprietary compound. The mechanism involves glutathione replenishment, as N-acetylcysteine is a precursor to glutathione, the body's primary endogenous antioxidant. The study was led by Dr. Premkumar Pugalenthi at Baylor. The sample size and duration were not fully specified in the source material. This is one of the few human trials to directly measure aging hallmarks as endpoints rather than clinical outcomes. The finding that a low-cost intervention can reverse aging hallmarks has significant implications for supplement accessibility.
GlyNAC supplementation reversed 9 hallmarks of aging in older adults in a Baylor University trial.
Sample size not specified in source. Aging hallmarks are mechanistic endpoints, not clinical outcomes. Needs replication in larger, longer trial.
From this page back to the goal it moves.
Cited by
1 encyclopedia entries reference this study.